{"id":"NCT03288987","sponsor":"AryoGen Pharmed Co.","briefTitle":"Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer","officialTitle":"A Phase III, Randomized, Two-armed, Triple Blinded, Parallel, Active Controlled Non-Inferiority Clinical Trial of Stivant (AryoGen Trastuzumab) Efficacy and Safety in Comparison to Avastin in Metastatic Colorectal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-04","primaryCompletion":"2018-07-30","completion":"2018-07-30","firstPosted":"2017-09-20","resultsPosted":"2021-01-22","lastUpdate":"2021-01-22"},"enrollment":126,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab + FOLFIRI-3","otherNames":["FOLFIRI-3 = irinotecan + calcium folinate + 5-fluorouracil"]}],"arms":[{"label":"Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)","type":"EXPERIMENTAL"},{"label":"Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial with a 2:1 allocation. This trial was conducted to evaluate the efficacy and safety of bevacizumab (produced by AryoGen Pharmed) plus FOLFIRI-3 compared with bevacizumab (Avastin®) plus FOLFIRI-3 in patients with metastatic colorectal cancer (mCRC). Patients who met the following criteria could be recruited to receive the mentioned intervention randomly. Inclusion criteria: male or female aged 18-75 years, mCRC verified histologically, Having one or more bi-dimensionally measurable lesions as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, Was not felt to be amenable to curative resection, With an (ECOG) performance status of ≤ 1, Life expectancy of longer than 3 months, Adequate organ and marrow function, May have received adjuvant therapy for primary colorectal cancer provided that at least 6 months have elapsed from the time the adjuvant therapy was concluded and recurrent disease was documented, Patients with history of hypertension must be well-controlled (blood pressure less than/equal to 150/100), on a stable regimen of anti-hypertensive therapy.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"PFS was measured from the start of chemotherapy to the date of disease progression or to the date of death if no progression whichever came first, assessed up to 12 months","effectByArm":[{"arm":"Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)","deltaMin":232,"sd":null},{"arm":"Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)","deltaMin":210,"sd":12.21}],"pValues":[{"comp":"OG000 vs OG001","p":"0.47"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":15},"locations":{"siteCount":22,"countries":["Iran"]},"refs":{"pmids":["32334845"],"seeAlso":["http://pubmed.ncbi.nlm.nih.gov/32334845/"]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":80},"commonTop":["Anaemia","Hyperglycaemia","Leukopenia","Neutropenia","Aspartate aminotransferase increased"]}}